MassDevice9h
Medtronic says Evolut TAVR shows durable five-year outcomes in low-risk patients
Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...
Healio8h
TAVR remains noninferior to surgery for low-risk patients at 5 years
Among patients with severe aortic stenosis at low surgical risk, transcatheter aortic valve replacement and surgery conferred ...
Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ ...
MedPage Today4h
Evolut Low Risk TAVR Still Chugging Along, Now Halfway to Trial's Finish Line
CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at ...
Hosted on MSN20d
Medtronic announces two-year trial outcomes of Evolut TAVR
Medtronic has announced the Small Annuli Randomized To Evolut or SAPIEN (SMART) head-to-head comparative trial’s two-year outcomes of the Evolut transfemoral transcatheter aortic valve replacement ...
TCTMD3d
What’s in a Name: Is It Time to Choose Between TAVI and TAVR?
With regional differences in which name is used for the aortic fix, some say unity is needed. Others can live with both.
Medscape10d
Better 5-Year Valve Performance With TAVI Than Surgery
Patients with symptomatic severe aortic stenosis undergoing CoreValve or Evolut TAVI have better 5-year bioprosthetic valve ...
Nasdaq20d
Medtronic : Data Confirms Superior Valve Performance Of Evolut TAVR System In Small Annulus Patients
(RTTNews) - Medtronic plc (MDT ... international head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR). In patients with aortic stenosis and a small aortic ...
Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy
Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...
AlphaGalileo1d
Dapagliflozin Safe and Effective in Elderly Patients with Heart Failure Undergoing Valve Replacement
Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve ...